Similarly in non-classical monocytes, CD169 percentage is increased in DMARD naïve (30.10% ± 18.41, 0.014), DMARD responder (30.95% ± 16.73, p < 0.001) and DMARD non-responder (30.68% ± 15.05, p < 0.001) RA patients compared to healthy controls (12.15% ± 8.392) (Figure 4B). The gene discussed is SIGLEC1; the disease is rheumatoid arthritis.